M Schmalzing1, A Strangfeld2, H-P Tony3. 1. Rheumatologie/klinische Immunologie, Medizinische Klinik und Poliklinik 2, Zentrum Innere Medizin, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland. schmalzing_m@ukw.de. 2. Programmbereich Epidemiologie, Gruppe Pharmakoepidemiologie, DRFZ - Deutsches Rheuma-Forschungszentrum, Charitéplatz 1, 10117, Berlin, Deutschland. 3. Rheumatologie/klinische Immunologie, Medizinische Klinik und Poliklinik 2, Zentrum Innere Medizin, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland.
Abstract
INTRODUCTION: Only insufficient data are available regarding the question whether treatment with immunosuppressants or biologicals is feasible and safe in patients with a history of malignancy. METHOD: Literature search via PubMed, EULAR abstracts and ACR abstracts from 2013 to 2015. RESULTS: The Société Francaise de Rhumatologie, the Canadian Rheumatology Association and the American College of Rheumatology have tried to make recommendations on this topic. Direct evidence mainly originates from data in three national registries which suggest that treatment with tumor necrosis factor (TNF) inhibitors and rituximab appears to be safe for carefully selected patients, at least if there is a longer interval between treatment with biologicals and oncological treatment. Furthermore, despite partly conflicting data all routine drugs for treating rheumatoid arthritis do not seem to show a consistently increased risk of de novo malignancies. The currently available data are presented for each drug of interest. CONCLUSION: Taking the current literature into account an attempt is made to formulate an algorithm for the medicinal treatment of patients with rheumatoid arthritis and a history of malignancy.
INTRODUCTION: Only insufficient data are available regarding the question whether treatment with immunosuppressants or biologicals is feasible and safe in patients with a history of malignancy. METHOD: Literature search via PubMed, EULAR abstracts and ACR abstracts from 2013 to 2015. RESULTS: The Société Francaise de Rhumatologie, the Canadian Rheumatology Association and the American College of Rheumatology have tried to make recommendations on this topic. Direct evidence mainly originates from data in three national registries which suggest that treatment with tumor necrosis factor (TNF) inhibitors and rituximab appears to be safe for carefully selected patients, at least if there is a longer interval between treatment with biologicals and oncological treatment. Furthermore, despite partly conflicting data all routine drugs for treating rheumatoid arthritis do not seem to show a consistently increased risk of de novo malignancies. The currently available data are presented for each drug of interest. CONCLUSION: Taking the current literature into account an attempt is made to formulate an algorithm for the medicinal treatment of patients with rheumatoid arthritis and a history of malignancy.
Authors: G Ruiz-Irastorza; A Ugarte; M V Egurbide; M Garmendia; J I Pijoan; A Martinez-Berriotxoa; C Aguirre Journal: Ann Rheum Dis Date: 2007-01-04 Impact factor: 19.103
Authors: Claire Bombardier; Glen S Hazlewood; Pooneh Akhavan; Orit Schieir; Anne Dooley; Boulos Haraoui; Majed Khraishi; Sharon A Leclercq; Jean Légaré; Dianne P Mosher; James Pencharz; Janet E Pope; John Thomson; Carter Thorne; Michel Zummer; Michael A Gardam; Johan Askling; Vivian Bykerk Journal: J Rheumatol Date: 2012-06-15 Impact factor: 4.666
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Michael E Weinblatt; Larry W Moreland; Rene Westhovens; Roger B Cohen; Sheila M Kelly; Nader Khan; Ramesh Pappu; Ingrid Delaet; Allison Luo; Sheila Gujrathi; Marc C Hochberg Journal: J Rheumatol Date: 2013-04-15 Impact factor: 4.666
Authors: Rachelle Buchbinder; Melissa Barber; Louise Heuzenroeder; Anita E Wluka; Graham Giles; Stephen Hall; Andrew Harkness; Daniel Lewis; Geoff Littlejohn; Marian H Miller; Peter F J Ryan; Damien Jolley Journal: Arthritis Rheum Date: 2008-06-15
Authors: Louise Kate Mercer; Audrey Sze Lin Low; James B Galloway; Kath D Watson; Mark Lunt; Deborah P M Symmons; Kimme L Hyrich Journal: Ann Rheum Dis Date: 2012-07-26 Impact factor: 19.103
Authors: Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy M Fleischmann; Daniel E Furst; Nicola Tyson; Neil Collinson; Patricia B Lehane Journal: Ann Rheum Dis Date: 2012-11-07 Impact factor: 19.103